Munch-a-Biotech Today Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1476)	2/20/2003 5:53:00 AM
From: Icebrg	Read Replies (1) of 3158

I don't really get this. It is too confusing. And not only because there turns out to be two ENZOs around. The Pharmaceuticals version with two ns (ENZN), which recently bought Abelcet from Elan, as well as the Biochem version (sans the final n - ENZ), which now intends to engage in a mutually exterminating munch together with NPSP). If I had been a shareholder in NPSP, I think I would be rather disappointed at this point. I cannot really see what excitement ENZ will be able to bring to the table. The immune regulation products are still in relatively early clinical development and the "gene stuff" is - well "gene stuff". And they say they have been working on this deal for a year. Amazing. But it must be something in the pipeline, that NPSP is looking at. It cannot be the cash as there isn't very much of that . As a sort of insurance, if Preos doesn't reach its primary endpoint of FDA-acceptance. Please explain! Will this make NPSP a more attractive company or not? Or is it just Hunter, who tries to expand his empire? Clearly it is ENZ who will turn out to be the less equal of partners in this transaction. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next